Name: Herclon 150mg Injection
Brand: Cipla Ltd.
SKU: 1299680
Price: 17390.00 INR
Availability: InStock

Question 1

How frequently heart investigations are required?

Accepted Answer

Heart investigations should be conducted at the start of treatment, then every 3 months during treatment, and every 6 months for 24 months after stopping Eleftha 150mg Injection. Patients with existing heart issues may need investigations every 12 weeks.

Question 2

How long should Eleftha 150mg Injection be taken?

Accepted Answer

Eleftha 150mg Injection should be taken for 1 year or until disease recurrence in patients with early breast cancer, whichever comes first. Treatment should not exceed 1 year.

Question 3

Why has my doctor advised for investigations of heart?

Accepted Answer

Eleftha 150mg Injection may negatively impact heart health when used with anthracycline anti-cancer medicines, so your doctor will monitor your heart health before and during treatment.

Question 4

What are the serious side effects of Eleftha 150mg Injection?

Accepted Answer

Serious side effects of Eleftha 150mg Injection include sore throat, fever, chills, excessive tiredness, pale skin, nosebleeds, unusual bruising or bleeding, stomach pain, seizures, hallucinations, muscle cramps, nausea, vomiting, loss of appetite, fatigue, rapid heartbeat, and changes in urine. Contact your doctor immediately if you experience any of these symptoms.

Question 5

Is fasting required before administering Eleftha 150mg Injection?

Accepted Answer

Fasting is not required before administering Eleftha 150mg Injection. It should be given under the supervision of a qualified healthcare professional experienced in cancer chemotherapy.

Question 6

How long after Eleftha 150mg Injection therapy can I get pregnant?

Accepted Answer

Women should use effective contraception during Eleftha 150mg Injection therapy and for 7 months after treatment before planning a pregnancy.

Question 7

Can Eleftha 150mg Injection be given to HER2 negative cancer patients?

Accepted Answer

Eleftha 150mg Injection is not suitable for HER2 negative cancer patients, as it targets the HER2 protein found on HER2 positive cancer cells to inhibit their growth.

Question 8

How is Eleftha 150mg Injection given, intravenously or intramuscularly?

Accepted Answer

Eleftha 150mg Injection is available in two formulations: one for intravenous infusion and another for subcutaneous injection. Ensure the correct formulation is used as prescribed, as the intravenous formulation is not for subcutaneous use. Your doctor may switch between formulations if appropriate.

Herclon 150mg Injection

Cipla Ltd.

Cipla Ltd.

Intas Pharmaceuticals Ltd.

Customers also bought

Disclaimer

Health Articles

Top Selling Medicines

Top Selling Devices

Health Articles